169 related articles for article (PubMed ID: 35968582)
1. Proton Pump Inhibitor Use and Obesity-Associated Cancer in the Women's Health Initiative.
Ballinger TJ; Djuric Z; Sardesai S; Hovey KM; Andrews CA; Brasky TM; Zhang JT; Rohan TE; Saquib N; Shadyab AH; Simon M; Wactawski-Wende J; Wallace R; Kato I
Nutr Cancer; 2023; 75(1):265-275. PubMed ID: 35968582
[TBL] [Abstract][Full Text] [Related]
2. Histamine H
Larson SR; Vasbinder AL; Reding KW; Leary PJ; Branch KR; Shadyab AH; Johnson KC; Haring B; Wallace R; Manson JE; Anderson G; Cheng RK
J Am Heart Assoc; 2022 Mar; 11(5):e024270. PubMed ID: 35191329
[TBL] [Abstract][Full Text] [Related]
3. Acid-suppressive medications and risk of colorectal cancer: results from three large prospective cohort studies.
Babic A; Zhang X; Morales-Oyarvide V; Yuan C; Khalaf N; Khalili H; Lochhead P; Chan AT; Ogino S; Wolpin BM; Wu K; Fuchs CS; Giovannucci EL; Stampfer MJ; Ng K
Br J Cancer; 2020 Sep; 123(5):844-851. PubMed ID: 32541871
[TBL] [Abstract][Full Text] [Related]
4. Use of Proton Pump Inhibitors vs Histamine 2 Receptor Antagonists for the Risk of Gastric Cancer: Population-Based Cohort Study.
Shin GY; Park JM; Hong J; Cho YK; Yim HW; Choi MG
Am J Gastroenterol; 2021 Jun; 116(6):1211-1219. PubMed ID: 34074826
[TBL] [Abstract][Full Text] [Related]
5. Clinical Use of Acid Suppressants and Risk of Dementia in the Elderly: A Pharmaco-Epidemiological Cohort Study.
Chen LY; Lin HJ; Wu WT; Chen YC; Chen CL; Kao J; You SL; Chou YC; Sun CA
Int J Environ Res Public Health; 2020 Nov; 17(21):. PubMed ID: 33182362
[TBL] [Abstract][Full Text] [Related]
6. Maintenance Proton Pump Inhibitor Use Associated with Increased All-Cause and Cause-Specific Mortality in Sweden.
Ngwenya S; Simin J; Brusselaers N
Dig Dis Sci; 2023 Jun; 68(6):2252-2263. PubMed ID: 36629968
[TBL] [Abstract][Full Text] [Related]
7. Proton Pump Inhibitor Use, H
Paik JM; Rosen HN; Gordon CM; Curhan GC
Calcif Tissue Int; 2018 Oct; 103(4):380-387. PubMed ID: 29754277
[TBL] [Abstract][Full Text] [Related]
8. Proton pump inhibitors are associated with a high rate of serious infections in veterans with decompensated cirrhosis.
Bajaj JS; Ratliff SM; Heuman DM; Lapane KL
Aliment Pharmacol Ther; 2012 Nov; 36(9):866-74. PubMed ID: 22966967
[TBL] [Abstract][Full Text] [Related]
9. Histamine-2 Receptor Antagonists and Proton Pump Inhibitors Are Associated With Reduced Risk of SARS-CoV-2 Infection Without Comorbidities Including Diabetes, Hypertension, and Dyslipidemia: A Propensity Score-Matched Nationwide Cohort Study.
Kim B; Jung JH; Han K; Kang S; Lee E; Chung H; Kim SG; Cho SJ
J Korean Med Sci; 2023 Apr; 38(13):e99. PubMed ID: 37012686
[TBL] [Abstract][Full Text] [Related]
10. Impact of concomitant acid suppressive therapy on pazopanib efficacy and dose reductions in patients with metastatic renal cell carcinoma.
Van De Sijpe G; Beuselinck B; Van Nieuwenhuyse T; Poncelet R; Bechter O; Albersen M; Roussel E; Baldewijns M; Tack J; Spriet I
Eur J Clin Pharmacol; 2020 Sep; 76(9):1273-1280. PubMed ID: 32474662
[TBL] [Abstract][Full Text] [Related]
11. Proton pump inhibitors and chronic kidney disease risk: a comparative study with histamine-2 receptor antagonists.
Kweon T; Kim Y; Lee KJ; Seo WW; Seo SI; Shin WG; Shin DH
Sci Rep; 2023 Dec; 13(1):21169. PubMed ID: 38036592
[TBL] [Abstract][Full Text] [Related]
12. Fracture risk of young adults receiving proton-pump inhibitors and H2-receptor antagonists.
Fedida B; Schermann H; Ankory R; Rotman D; Shichman I; Yoffe V; Shlaifer A; Luger E
Int J Clin Pract; 2019 May; 73(5):e13339. PubMed ID: 30829427
[TBL] [Abstract][Full Text] [Related]
13. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.
Leontiadis GI; Sreedharan A; Dorward S; Barton P; Delaney B; Howden CW; Orhewere M; Gisbert J; Sharma VK; Rostom A; Moayyedi P; Forman D
Health Technol Assess; 2007 Dec; 11(51):iii-iv, 1-164. PubMed ID: 18021578
[TBL] [Abstract][Full Text] [Related]
14. Proton pump inhibitors and risk of gastric cancer: a population-based cohort study.
Poulsen AH; Christensen S; McLaughlin JK; Thomsen RW; Sørensen HT; Olsen JH; Friis S
Br J Cancer; 2009 May; 100(9):1503-7. PubMed ID: 19352380
[TBL] [Abstract][Full Text] [Related]
15. Comparative risk of incidence and clinical outcomes of COVID-19 among proton pump inhibitor and histamine-2 receptor antagonist short-term users: a nationwide retrospective cohort study.
Park J; You SC; Cho J; Park CH; Shin WG; Park RW; In Seo S
BMC Pharmacol Toxicol; 2022 Jan; 23(1):9. PubMed ID: 35039078
[TBL] [Abstract][Full Text] [Related]
16. Safety of Concomitant Metformin and Proton Pump Inhibitor Use: A Population Retrospective Cohort Study.
Chen CB; Lin M; Eurich DT; Johnson JA
Clin Ther; 2016 Jun; 38(6):1392-1400. PubMed ID: 27061884
[TBL] [Abstract][Full Text] [Related]
17. The combined use of anti-peptic agents is associated with an increased risk of osteoporotic fracture: a nationwide case-control study.
Oh DJ; Nam JH; Lee HS; Moon YR; Lim YJ
Korean J Intern Med; 2024 Mar; 39(2):228-237. PubMed ID: 38321358
[TBL] [Abstract][Full Text] [Related]
18. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease.
Lazarus B; Chen Y; Wilson FP; Sang Y; Chang AR; Coresh J; Grams ME
JAMA Intern Med; 2016 Feb; 176(2):238-46. PubMed ID: 26752337
[TBL] [Abstract][Full Text] [Related]
19. Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans.
Xie Y; Bowe B; Li T; Xian H; Yan Y; Al-Aly Z
BMJ Open; 2017 Jul; 7(6):e015735. PubMed ID: 28676480
[TBL] [Abstract][Full Text] [Related]
20. Proton pump inhibitors and hypomagnesemia in the general population: a population-based cohort study.
Kieboom BC; Kiefte-de Jong JC; Eijgelsheim M; Franco OH; Kuipers EJ; Hofman A; Zietse R; Stricker BH; Hoorn EJ
Am J Kidney Dis; 2015 Nov; 66(5):775-82. PubMed ID: 26123862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
